论文部分内容阅读
目的观察新辅助化疗辅以循环肿瘤细胞(CTC)检测对乳腺癌的治疗效果分析。方法 50例乳腺癌患者经评估后采用新辅助化疗,观察化疗前、化疗2、4、6周期后的治疗效果、CTC阳性率。结果 50例患者治疗后完全缓解31例(62%)、部分缓解5例(10%)、疾病稳定7例(14%)及疾病进展7例(14%),总有效率为72%。化疗前及化疗2周期、4周期、6周期后CTC的阳性率呈逐渐下降状态,平均每7.5 ml外周血中的CTC个数也呈下降状态。结论新辅助化疗不仅能有效缩小乳腺癌原发灶,预示药敏,同时降低外周血CTC水平,减少肿瘤可能存在的转移及复发风险。
Objective To observe the effect of neoadjuvant chemotherapy combined with circulating tumor cells (CTC) on breast cancer. Methods Fifty patients with breast cancer were evaluated by neoadjuvant chemotherapy. The therapeutic effect and CTC positive rate before and after chemotherapy were observed. Results Fifty patients achieved complete remission in 31 cases (62%), partial remission in 5 cases (10%), stable disease in 7 cases (14%) and disease progression in 7 cases (14%) after treatment. The total effective rate was 72%. The positive rates of CTC in 2 cycles, 4 cycles and 6 cycles before chemotherapy were gradually decreased, and the average number of CTCs in 7.5 ml peripheral blood also decreased. Conclusion Neoadjuvant chemotherapy can not only effectively reduce the primary tumor of breast cancer, indicating the drug sensitivity, reduce the level of CTC in peripheral blood and reduce the possible metastasis and recurrence risk of tumor.